SARS-CoV-2 Recombinant Protein Vaccine, strain D614 (Sanofi/Glaxosmithkline)

N/A

Report date: 2024/11/18 10:09:45

Base Information

Drug NameSARS-CoV-2 Recombinant Protein Vaccine, strain D614 (Sanofi/Glaxosmithkline)
Drug Alias NameVaccin SP/GSK, CoV2 preS dTM-AS03 adjuvanted vaccine, strain D614Adjuvanted recombinant protein-based COVID-19 vaccine (Sanofi/Glaxosmithkline)VidPrevtynGSK-4353001ASP-0253
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineUganda +[16] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSanofi PasteurGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcSanofi Pasteur
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeJ07BX03
Related LinksN/A